8-(biaryl)quinoline PDE4 inhibitors

Details 8-(biaryl)quinoline PDE4 inhibitors 8-(biaryl)quinoline PDE4 inhibitors

2006-12-26

2006-12-26

Seaman, D. Margaret (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S173000, C514S311000, C514S314000

Reexamination Certificate

active

07153968

ABSTRACT:
8-(biaryl) quinolines wherein the bi-aryl group at the 8-position is in a meta relationship to the quinoline group, are PDE4 inhibitors useful in the treatment of asthma, chronic bronchitis, chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock, laminitis in horses, colic in horses, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, ortherosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, ankylosing spondylitis, transplant rejection, graft versus host disease, hypersecretion of gastric acid, bacterial, fungal induced sepsis, viral induced sepsis, fungal induced septic shock, viral induced septic shock, inflammation-mediated chronic tissue degeneration, cytokine-mediated chronic tissue degeneration, osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, tumour growth, or cancerous invasion of normal tissues. In another aspect, the present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a safe and cognition enhancing amount of a phosphodiesterase-4 inhibitor.

REFERENCES:
patent: 5455252 (1995-10-01), Wilhelm et al.
patent: 5530005 (1996-06-01), Wilhelm et al.
patent: 6069151 (2000-05-01), Dyke et al.
patent: WO 02/094823 (2002-11-01), None
MacDonald, D. et al., Journal of Medicinal Chemistry, vol. 43, No. 21, pp. 3820-3823, (2000).
Houslay, et al—Drug Discovery Today, 10 (22) pp. 1503-1519, 2005.
Meijsing, et al—Cancer Letters, 188, pp. 53-58, 2002.
Ochi, et al—Life Sciences, 77, pp. 2040-2050, 2005.
Compton, et al—The Lancet, vol. 358, pp. 265 270, 2001.
Rabe, et al—The Lancet, vol. 366, pp. 563-571, 2005.
Rose, et al—Current Pharmaceutical Design, vol. 11, pp. 3329-3334, 2005.

Affiliated with

Also associated with

Rating

8-(biaryl)quinoline PDE4 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 8-(biaryl)quinoline PDE4 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 8-(biaryl)quinoline PDE4 inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3720407